// Biotech and Pharma Therapeutics
Sanofi, Regeneron’s Dupixent tops TV spending again, with AbbVie’s Rinvoq close behind
Summer ended much as it began for pharma TV ad spending—Sanofi and Regeneron’s anti-inflammatory med Dupixent remains in the top spot. Meanwhile, the perennial No. 1 it displaced—AbbVie’s blockbuster Humira—continues in the middle of the pack, while next-gen brand Rinvoq continues its TV commercial …
www.fiercepharma.com
Biogen CEO blames Aduhelm’s rocky launch on ‘too much confusion, misinformation and controversy’
Before Biogen scored an FDA approval for Alzheimer’s drug aducanumab, the company probably hoped its launch would go much smoother than the last three months have been. It turns out Biogen’s CEO Michel Vounatsos is willing to say so publicly.
www.fiercepharma.com
Eli Lilly to donate nearly $1M to Type 1 diabetes initiative - Drug Delivery Business
Eli Lilly announced today that it will commit nearly $1 million over the next three years toward helping children with Type 1 diabetes.
www.drugdeliverybusiness.com
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration | BioSpace
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration - read this article along with other careers information, tips and advice on BioSpace
www.biospace.com
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss | BioSpace
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss - read this article along with other careers information, tips and advice on BioSpace
www.biospace.com
// 4th Industrial Revolution
Utilizing machine learning to improve clinical trial design for acute respiratory distress syndrome - npj Digital Medicine
Heterogeneous patient populations, complex pharmacology and low recruitment rates in the Intensive Care Unit (ICU) have led to the failure of many clinical trials. Recently, machine learning (ML) emerged as a new technology to process and identify big data relationships, enabling a new era in clinical trial design.
www.nature.com
.jpg)
Wearable fitness company WHOOP acquires sports tech startup PUSH
The acquisition announcement comes just after WHOOP reported it had raised $200 million in Series F funding.
www.mobihealthnews.com
Clinova launches health and wellness search engine with Caidr 3.0
UK-based digital healthcare company Clinova has launched Caidr 3.0, the latest version of its health and wellness search engine for smart self-care. Key features include a search tool for health topics, treatments and products and messages and content on wellbeing and local advice on health while travelling abroad.
www.mobihealthnews.com
How entrepreneurs can meet the moment in digital healthcare innovation - MedCity News
As the popularity of digital healthcare only continues to grow, the innovative entrepreneurs who balance all factors of the ‘consumer’ patient experience will find the highest adoption.
medcitynews.com
Startup Modulus embraces AI to design better NK cell therapies for cancer - MedCity News
Modulus Therapeutics recently emerged from stealth with technology from various disciplines and seed funding that the startup is using to develop better cell therapies. Natural killer cells directed against breast cancer is Modulus’s initial focus, but the startup says its approach can apply to mult…
medcitynews.com
// Business & Markets
/https%3A%2F%2Fspecials-images.forbesimg.com%2Fimageserve%2F613a0a597e115b450688b150%2F0x0.jpg)
Mammoth Biosciences Raises $195 Million, Vaulting Its Crispr Tech To Unicorn Status
Investors are betting the protein toolbox of the four-year-old startup can solve one of gene therapy’s trickiest problems: getting treatments into the patient’s body.
www.forbes.com
How CVS Health Drives Cardinal Health’s Distribution Financials
Catalent has kept busy during the pandemic by helping vaccine heavyweights scale up their supply chains. In an expansion bid beyond its ongoing pandemic work, the company is buying a leading producer of gummies in the nutritional supplements field.
www.drugchannels.net
Baxter, looking to accelerate connected care, will acquire Hillrom for $10.5B
The companies say their complementary products will support patients in the hospital, at home and in alternate sites of care.
www.healthcareitnews.com
RNA Editor ProQR Lines Up $1.5 Billion Deal with Eli Lilly | BioSpace
The partnership combines the companies’ resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner.
www.biospace.com
Roche’s Genentech inks $3bn+ pact with Adaptimmune to make cell therapies ‘curative and mainstream’
Adaptimmune Therapeutics, which focuses on solid tumors, has announced a tie-up with Roche’s Genentech to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.
www.biopharma-reporter.com
// Legal & Regulatory
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021 - European Medicines Agency
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021
www.ema.europa.eu
Cancer concerns lead FDA to place clinical hold on BioMarin gene therapy - MedCity News
A Phase 1/2 study of BioMarin Pharmaceutical’s gene therapy for phenylketonuria has been placed under a clinical hold after interim results from a preclinical study showed that some mice developed liver tumors. Patients did not receive the same high dose that was given to the mice, and no one in the…
medcitynews.com
FDA approves Impel NeuroPharma’s nasal spray for treating migraines - Drug Delivery Business
Impel NeuroPharma (NSDQ:IMPL) announced today that the FDA approved its Trudhesa nasal spray for treating migraine in adults.
www.drugdeliverybusiness.com
Settling lawsuit, AstraZeneca and European Commission agree on coronavirus vaccine delivery
The U.K.-based drugmaker fell behind on its promise to supply 300 million doses by the end of June to countries in the trading bloc. Now, it’s set to reach that target by March 2022.
www.biopharmadive.com
‘The sky is not falling.’ Cautious optimism follows FDA meeting on gene therapy risks
Wall Street analysts expect little impact on biotech developers after an inconclusive discussion last week. Yet the FDA still appears wary, as shown by a new hold on a BioMarin rare disease treatment.
www.biopharmadive.com
// Research & Development
Science 37 teams up with Roche’s Foundation Medicine to boost home-based oncology trials
Cancer trials typically have to be done within a hospital or community healthcare setting, but Science 37 and Roche’s genomics unit Foundation Medicine are teaming up to move some of this to an at-home setting.
www.fiercebiotech.com
WHO calls for coordinated dementia research efforts, looks to drive innovation in the field
Previously a series of unsuccessful clinical trials for treatments, combined with the high costs of R&D in the area, led to declining interest in dementia research but a new publication from the WHO notes a definite uptick in the funding of such work in more recent times.
www.biopharma-reporter.com
Increasingly savvy patients call for shift in trial approach: Illingworth
A leader from the home trial services provder says patients’ increasing awareness of clinical research has how trial teams should consider their approach.
www.outsourcing-pharma.com
// Politics
Biden Administration Announces National Cybersecurity Initiatives
The Biden Administration met with top cybersecurity leaders to discuss national cybersecurity initiatives following President Biden’s executive order in May.
healthitsecurity.com
Florida nursing home group fears staffing challenges after Biden issues COVID vaccine requirement
After President Biden announced the plan for COVID vaccinations for healthcare workers, the Florida Health Care Association, the state’s largest nursing-home group, quickly raised concerns that the requirement would worsen staffing shortages and apply only to nursing homes.
www.sun-sentinel.com
